Best- and Worst-Performing Stocks of July 2024
DR Horton and Charter Communications rank among the best stocks for the month, while the worst include CrowdStrike and Edwards Lifesciences.
The Morningstar US Large-Mid Cap Index rose 1.2% in July amid a rally in the financial services sector. The index tracks the performance of the top 90% of the US investable universe by market cap. Each month we screen the index to find the best- and worst-performing companies. Data in this article is sourced from Morningstar Direct.
Best-Performing Stocks of July 2024
Worst-Performing Stocks of July 2024
Metrics for the Best-Performing Stocks
Stanley Black & Decker SWK
- Sector: Industrials
- Industry: Tools & Accessories
- Economic Moat: Not Rated
Black & Decker climbed 32.2% in July, lifting shares 10.3% over the past year. The company’s stock has a quantitative Morningstar Rating of 3 stars.
DR Horton DHI
- Sector: Consumer Cyclical
- Industry: Residential Construction
- Economic Moat: None
DR Horton climbed 27.7%, lifting shares 42.9% over the past year. The company’s stock has a Morningstar Rating of 2 stars and is trading at a 23% premium to its fair value estimate of $146 per share.
Charter Communications CHTR
- Sector: Communication Services
- Industry: Telecom Services
- Economic Moat: Narrow
Charter rose 27.0%, but shares were still down 6.3% over the past year. Shares are 17.1% below their last high on Oct. 16, 2023. The company’s stock has a Morningstar Rating of 4 stars and is trading at a 23% discount to its fair value estimate of $490 per share.
CBRE Group CBRE
- Sector: Real Estate
- Industry: Real Estate Services
- Economic Moat: Narrow
CBRE rose 26.5%, bringing it up 35.3% from one year ago. The company’s stock has a Morningstar Rating of 3 stars and is trading at a 15% premium to its fair value estimate of $98 per share.
Avantor AVTR
- Sector: Basic Materials
- Industry: Specialty Chemicals
- Economic Moat: Not Rated
Avantor jumped 26.2%, leaving it up 30.0% for the year. The company’s stock has a quantitative Morningstar Rating of 3 stars.
Metrics for the Worst-Performing Stocks
DexCom DXCM
- Sector: Healthcare
- Industry: Medical Devices
- Economic Moat: None
DexCom slid 40.2% in July, down 45.6% from one year ago. Shares are 52.2% below their last high on March 26, 2024. The company’s stock has a Morningstar Rating of 4 stars and is trading at a 28% discount to its fair value estimate of $94 per share.
CrowdStrike CRWD
- Sector: Technology
- Industry: Software - Infrastructure
- Economic Moat: Narrow
CrowdStrike slid 39.5%, but shares were still up 43.5% for the year. Shares are 41.8% below their last high on July 9, 2024. The company’s stock has a Morningstar Rating of 4 stars and is trading at a 23% discount to its fair value estimate of $300 per share.
Edwards Lifesciences EW
- Sector: Healthcare
- Industry: Medical Devices
- Economic Moat: Narrow
Edwards tumbled 31.7%, down 23.2% from one year ago. Shares are 34.4% below their last high on March 28, 2024. The company’s stock has a Morningstar Rating of 4 stars and is trading at a 25% discount to its fair value estimate of $84 per share.
Lamb Weston Holdings LW
- Sector: Consumer Defensive
- Industry: Packaged Foods
- Economic Moat: Narrow
Lamb Weston fell 28.6%, down 41.3% from one year ago. Shares are 46.4% below their last high on Jan. 4, 2024. The company’s stock has a Morningstar Rating of 4 stars and is trading at a 37% discount to its fair value estimate of $95 per share.
Pinterest PINS
- Sector: Communication Services
- Industry: Internet Content & Information
- Economic Moat: Narrow
Pinterest slid 27.5%, but shares were still up 10.2% for the year. Shares are 29.3% below their last high on June 25, 2024. The company’s stock has a Morningstar Rating of 4 stars and is trading at a 26% discount to its fair value estimate of $43 per share.
Companies that are not formally covered by a Morningstar analyst are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative star rating.
This article was generated with the help of automation and reviewed by Morningstar editors. Learn more about Morningstar’s use of automation.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.